<DOC>
	<DOCNO>NCT00112853</DOCNO>
	<brief_summary>This phase I trial study side effect best dose tipifarnib etoposide treat old patient newly diagnose acute myeloid leukemia . Tipifarnib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , etoposide , work different way stop growth cancer cell , either kill cell stop divide . Giving tipifarnib together etoposide may kill cancer cell</brief_summary>
	<brief_title>Tipifarnib Etoposide Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility , tolerability , toxicity administer fix dose R115777 combination escalate dos VP-16 elderly adult ( = 70 year ) newly diagnose , previously untreated acute myelogenous leukemia ( AML ) . II . To determine maximal tolerate dose ( MTD ) R115777 + VP-16 combination , include duration R115777 administration , future Phase II trial . III . To obtain preliminary descriptive data regard effect R115777 + VP-16 cell cycle progression apoptosis AML marrow cell . IV . To study mechanism leukemia cell resistance R115777 combination etoposide . OUTLINE : This multicenter , dose-escalation study . Patients receive oral tipifarnib twice daily day 1-14 OR 1-21 oral etoposide daily day 1-3 8-10 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) may receive 5 additional course therapy beyond documentation CR . Cohorts 3-6 patient receive escalate dos tipifarnib etoposide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 14 additional patient receive treatment MTD . After completion study treatment , patient follow 1 month every 3 month thereafter . PROJECTED ACCRUAL : A total 3-100 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Adults age establish , pathologically confirm diagnose newly diagnose AML , include de novo secondary AMLs exclude newly diagnose acute progranulocytic leukemia ( APL , M3 ) , consider eligible study ECOG performance status 02 Patient must able give informed consent Serum creatinine = &lt; 2.0 mg/dl SGOT SGPT = &lt; 5 x upper limit normal ( ULN ) Bilirubin = &lt; 2 mg/dl Diseasespecific criterion : Newly diagnose AML , subtypes M0,1,2,47 exclude M3 ( APL ) , include myelodysplasia ( MDS ) relate AML ( MDS/AML ) treatmentrelated AML Patients receive hydroxyurea alone receive noncytotoxic therapy previously MDS ( e.g. , thalidomide , interferon , cytokine , 5azacytidine ) eligible trial Any previous treatment R115777 VP16 Patients receive concomitant chemotherapy , radiation therapy immunotherapy Hyperleukocytosis &gt; = 30,000 blasts/uL rapidly rise blast count project doubling time = &lt; 2 day Acute progranulocytic leukemia ( APL , M3 ) Active CNS leukemia Active , uncontrolled infection ; patient infection active treatment control antibiotic eligible Presence lifethreatening illness Patients mental deficit and/or psychiatric history preclude give informed consent follow protocol Patients enzymeinducing anticonvulsant ( e.g. , phenytoin , fosphenytoin , phenobarbital , primidone , carbamazepine , oxcarbazepine ) ; patient may change nonenzyme induce anticonvulsant stabilize start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>